Immune Design (IMDZ) Misses Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/3/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
- Analysis-Excommunications show a Pope Leo unafraid of making firm decisions
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Canaccord Starts Infleqtion, Inc (INFQ) at Buy
- Jersey Mike's Subs files for IPO on NYSE under ticker JMKE
- Meta CEO Mark Zuckerberg Says In Internal Town Hall That Ai Agent Development Over The Last Four Months Hasn't 'accelerated In The Way We Expected' - Reuters
Immune Design Reports Second Quarter 2015 Financial Results
August 12, 2015 4:01 PM EDTSEATTLE and SOUTH SAN FRANCISCO, Calif., Aug. 12, 2015 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), a clinical-stage immunotherapy company focused on oncology, today reported financial results and a corporate update for the second quarter ended June 30, 2015, which included the announcement of three new immuno-oncology clinical collaborations and a cash position of $129.0 million, inclusive of net proceeds from a public offering in April 2015.
Corporate Update and Recent Highlights
On August 10, 2015, Immune Design announced it had entered into two clinical trial collaborations with Merck (NYSE: MRK) to evaluate two immuno-oncology... MoreImmune Design Reports Second Quarter 2015 Financial Results
August 12, 2015 4:01 PM EDTSEATTLE and SOUTH SAN FRANCISCO, Calif., Aug. 12, 2015 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), a clinical-stage immunotherapy company focused on oncology, today reported financial results and a corporate update for the second quarter ended June 30, 2015, which included the announcement of three new immuno-oncology clinical collaborations and a cash position of $129.0 million, inclusive of net proceeds from a public offering in April 2015.
Corporate Update and Recent Highlights
On August 10, 2015, Immune Design announced it had entered into two clinical trial collaborations with Merck (NYSE: MRK) to evaluate two immuno-oncology... More